Anesthetic, Local Patents (Class 514/818)
-
Patent number: 8652443Abstract: Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents.Type: GrantFiled: February 13, 2009Date of Patent: February 18, 2014Assignee: Precision Dermatology, Inc.Inventors: Ravi K. Varanasi, Roman V. Rariy
-
Patent number: 8530502Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.Type: GrantFiled: May 8, 2009Date of Patent: September 10, 2013Assignee: Dr. N's Health Care Products, LLCInventor: Alfred A. Nickel
-
Patent number: 8523569Abstract: The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means.Type: GrantFiled: December 22, 2008Date of Patent: September 3, 2013Inventor: Khashayar Kevin Neshat
-
Patent number: 8420600Abstract: The present invention is directed to compositions and methods for relieving pain at a site in a human or animal by administering at a discrete site in a human or animal a dose of capsaicin in an amount effective to denervate the discrete site without eliciting an effect outside the discrete location.Type: GrantFiled: August 7, 2006Date of Patent: April 16, 2013Assignee: Vallinex, Inc.Inventors: Ronald Burch, Richard B. Carter, Jeff Lazar
-
Patent number: 8367733Abstract: The present invention is directed to methods for attenuating pain associated with a surgical site or an open wound by administration of single doses of a capsaicinoid formulation in proximity to a surgical site or wound opening.Type: GrantFiled: August 7, 2006Date of Patent: February 5, 2013Assignee: Vallinex, Inc.Inventors: Ronald Burch, Richard B. Carter, Jeff Lazar
-
Patent number: 8304234Abstract: Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV am disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.Type: GrantFiled: December 23, 2005Date of Patent: November 6, 2012Assignees: The Trustees of the Universtiy of Pennsylvania, The Wistar InstituteInventors: David B. Weiner, William V. Williams, Bin Wang
-
Patent number: 8241660Abstract: This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.Type: GrantFiled: August 20, 2007Date of Patent: August 14, 2012Inventor: Martin Wenckens
-
Patent number: 8158682Abstract: This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the pharmaceutical composition to dwell for a predetermined period of time, and aspirating the wound or incision to remove the pharmaceutical composition. The invention also provides a method for attenuating pain in proximity to a joint comprising intra-articularly injecting a pharmaceutical composition comprising a capsaicinoid into the joint, allowing the pharmaceutical composition to dwell for predetermined period of time, and aspirating the joint to remove the pharmaceutical composition. In certain embodiments of the invention, the capsaicinoid is capsaicin.Type: GrantFiled: September 14, 2009Date of Patent: April 17, 2012Assignee: Vallinex, Inc.Inventors: Lakshmi Sangameswaran, Susan Kramer
-
Patent number: 7998503Abstract: The invention relates to a nasally applied, film-shaped, bioadhesive pharmaceutical form of administration containing at least one agent-containing layer that is based on crosslinked hydrophilic polymers comprising up to 60 percent by weight of Lidocaine, the percentage being in relation to the total quantity of crosslinked hydrophilic polymers. Also disclosed is the use thereof for controlling primary headaches, preferably migraine.Type: GrantFiled: December 13, 2004Date of Patent: August 16, 2011Assignee: LTS Lohmann Therapie-Systeme AGInventors: Rasoul Sedaghat Kerdar, Maria Cristina Vázquez Lantes
-
Patent number: 7964644Abstract: The invention relates to using neurotoxic substances which in particular are toxic to the axons and to the nociceptive nerve endings in the preparations of agents treating joint pains.Type: GrantFiled: July 19, 2002Date of Patent: June 21, 2011Assignee: MESTEX AGInventor: Dominik Meyer
-
Patent number: 7666914Abstract: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment which comprise applying the various disclosed combinations of agents to the patient's skin.Type: GrantFiled: June 3, 2004Date of Patent: February 23, 2010Inventors: David M. Richlin, George R. Doherty
-
Patent number: 7575757Abstract: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Type: GrantFiled: March 18, 2005Date of Patent: August 18, 2009Assignee: Novalar Pharmaceuticals, Inc.Inventors: Andrew X. Chen, Julius Knowles, Eckard Weber
-
Patent number: 7569230Abstract: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Type: GrantFiled: December 15, 2006Date of Patent: August 4, 2009Assignee: Novalar Pharmaceuticals, Inc.Inventors: Andrew X Chen, Julius Knowles, Eckard Weber
-
Patent number: 7425340Abstract: A transdermal or topical composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects.Type: GrantFiled: May 2, 2005Date of Patent: September 16, 2008Assignee: Antares Pharma IPL AGInventors: Arnaud Grenier, Dario Norberto R. Carrara, Celine Besse
-
Patent number: 7090866Abstract: This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as active ingredient, an opioid (? receptor) agonist, such as fentanyl, or a salt thereof, characterized in that the composition is in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity. A process for preparing such a composition and the use of such a composition as an analgesic, for the treatment of chronic pain and/or breakthrough pain, as an anesthetic premedication, for the induction of anesthesia, as a sedative and/or for the treatment of anxiety are also provided.Type: GrantFiled: August 25, 2003Date of Patent: August 15, 2006Assignee: R.P. Scherer Technologies, Inc.Inventors: Edward Stewart Johnson, Jon Lacy
-
Patent number: 7041705Abstract: Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic aent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.Type: GrantFiled: March 26, 2001Date of Patent: May 9, 2006Assignee: Jagotec AGInventors: Awadhesh K. Mishra, Gary W. Pace, Michael G Vachon
-
Patent number: 7030100Abstract: Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia. However, the roles of effectors for cGMP are not fully understood in the processing of pain in the spinal cord. cGMP-dependent protein kinase (PKG) I? but not PKGI? was localized in the neuronal bodies and processes, and was distributed primarily in the superficial laminae of the spinal cord. Intrathecal administration of an inhibitor of PKGI?, Rp-8-[(4-Chlorophenyl)thio]-cGMPS triethylamine, produces significant antinociception. Moreover, PKGI? protein expression was dramatically increased in the lumbar spinal cord after noxious stimulation. This upregulation of PKGI? expression was completely blocked not only by a neuronal NO synthase inhibitor, and a soluble guanylate cyclase inhibitor, but also by an N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801.Type: GrantFiled: June 28, 2002Date of Patent: April 18, 2006Assignee: Johns Hopkins UniversityInventors: Yuanxiang Tao, Roger A. Johns
-
Patent number: 7001759Abstract: Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional, or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against pathogens are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.Type: GrantFiled: July 23, 1999Date of Patent: February 21, 2006Assignees: The Trustees of the University of Pennsylvania, The Wistar InstituteInventors: David B. Weiner, William V. Williams, Bin Wang
-
Patent number: 6953590Abstract: A preparation for transdermal absorption is disclosed which is suited for alleviating lasting pains caused by herpes zoster or postherpetic neuralgia and is practical and more improved in drug efficacy, safety and application characteristics. This tape preparation for transdermal absorption is obtained by causing an adhesive mass prepared by incorporating 1–30 parts by weight of a local anesthetic as an active ingredient in 100 parts by weight of a nonaqueous adhesive mass base comprising 5–50% by weight of a styrene-isoprene-styrene block copolymer, 1–60% by weight of an alicyclic saturated hydrocarbon resin, 5–60% by weight of liquid paraffin and 1–30% by weight of butyl rubber to be supported on a backing.Type: GrantFiled: September 9, 1999Date of Patent: October 11, 2005Assignees: Yutoku Pharmaceutical Ind. Co., Ltd., Maruho Kabushiki KaishaInventors: Yukino Owaki, Michiyo Hashimoto, Isamu Sakamoto, Kunio Takiguchi, Yoetsu Toyoshima
-
Patent number: 6921541Abstract: A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.Type: GrantFiled: September 9, 2002Date of Patent: July 26, 2005Assignee: Euro-Celtique S.A.Inventors: Mark Chasin, Paul Goldenheim, Richard Sackler, Joseph Tigner, Ronald M Burch
-
Patent number: 6894078Abstract: A method for applying a topical anesthetic to an area of skin comprising the steps of a) incorporating an anesthetic in a lipophilic base into a volatile solvent, to form a homogeneous solution; b) applying the homogeneous solution into the area of skin to be treated; and c) evaporating the volatile solvent from the homogeneous solution; wherein the volatile solvent is present in the formulation in amounts between 40-80%; and wherein said topical anesthetic rapidly penetrates the skin surface at said skin, leaving a cooling sensation on the skin. The topical anesthetic formulation contains a penetrating enhancer carrier that markedly enhances the delivery of the anesthetic across human skin without altering the acceptable delivery rate of the anesthetic that needs to be delivered through the skin and leaves a cooling sensation on the skin.Type: GrantFiled: September 17, 2001Date of Patent: May 17, 2005Inventor: James G. Castillo
-
Patent number: 6881756Abstract: The present invention relates to a method for reducing inflammation in the skin and/or treating inflammatory skin disorders, pain, or pruritis by topically applying a composition comprising totarol or a pharmaceutically-acceptable ester thereof.Type: GrantFiled: September 17, 2002Date of Patent: April 19, 2005Assignee: Johnson & Johnson Consumer Companies, Inc.Inventor: Gerard J. Gendimenico
-
Patent number: 6872390Abstract: Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.Type: GrantFiled: May 28, 2002Date of Patent: March 29, 2005Assignee: Novalar Pharmaceuticals, Inc.Inventors: Eckard Weber, Howard I. Katz
-
Patent number: 6774131Abstract: A pharmaceutical composition for therapeutically treating prostate cancer, the pharmaceutical composition containing N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyri midinyl]-2-phenylethenesulfoneamide or a pharmaceutically acceptable salt thereof as the effective component.Type: GrantFiled: July 19, 2002Date of Patent: August 10, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hironori Yuyama, Akira Fujimori, Masanao Sanagi, Hironori Harada, Akiko Koakutsu, Mikiko Mori, Nobuyuki Yamamoto
-
Patent number: 6764678Abstract: Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.Type: GrantFiled: May 28, 2002Date of Patent: July 20, 2004Assignee: Novalar Pharmaceuticals, Inc.Inventors: Eckard Weber, Howard I. Katz
-
Patent number: 6713527Abstract: The invention relates to surgical bone cement compositions and more particularly to bone cement compositions having aneasthetic properties, and to methods for producing analgesia.Type: GrantFiled: November 15, 2001Date of Patent: March 30, 2004Assignee: Queen's University at KingstonInventors: David M. Bond, John F. Rudan, Michael A. Adams
-
Patent number: 6699908Abstract: Methods and formulations for inducing substantially safer local anesthesia in a patient are provided. The methods comprise administering, to a patient in need thereof, a substrate containing a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material to safely obtain a reversible nerve blockade when implanted or injected in a patient.Type: GrantFiled: September 26, 2001Date of Patent: March 2, 2004Assignee: Euro-Celtique, S.A.Inventors: Richard S. Sackler, Paul D. Goldenheim, Mark Chasin, Ronald M. Burch, Robert F. Reder, Joseph Tigner
-
Patent number: 6680071Abstract: This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as active ingredient, an opioid (&mgr;receptor) agonist, such as fentanyl, or a salt thereof, characterized in that the composition is in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity. A process for preparing such a composition and the use of such a composition as an analgesic, for the treatment of chronic pain and/or breakthrough pain, as an anesthetic premedication, for the induction of anesthesia, as a sedative and/or for the treatment of anxiety are also provided.Type: GrantFiled: January 14, 2002Date of Patent: January 20, 2004Assignee: R. P. Scherer Technologies, Inc.Inventors: Edward Stewart Johnson, Jon Lacy
-
Patent number: 6638966Abstract: Melatonin (N-acetyl-5-methoxytryptamine), or its biologically active analogues, are used to induce anesthesia.Type: GrantFiled: February 19, 2002Date of Patent: October 28, 2003Assignee: University of Iowa Research FoundationInventors: Max T. Baker, Mohamed Naguib Attala
-
Patent number: 6635236Abstract: A method for treating podotrochlosis (navicular disease/navicular syndrome) in the foot of a horse is disclosed. The method comprises identifying the specific area(s) of the horse's foot affected by navicular disease and applying at least one extracorporeal shockwave to the affected area(s). In a preferred embodiment, a sonar-emitting device is used to identify the areas within the foot affected by podotrochlosis.Type: GrantFiled: August 10, 2001Date of Patent: October 21, 2003Inventor: Knut Bär
-
Patent number: 6599906Abstract: The present invention provides a method of producing local analgesia and anesthesia in a mammal experiencing pain in a nerve tissue region. The method includes topically administrating to the region, in a suitable pharmaceutical vehicle, an effective dose of a sodium channel blocking compound.Type: GrantFiled: November 1, 2000Date of Patent: July 29, 2003Assignee: Wex Medical Instrumentation Co., Ltd.Inventors: Baoshan Ku, Shiquan Qi
-
Patent number: 6569839Abstract: A pharmaceutical composition comprising at least one local anesthetic, at least one anti-inflammatory agent and at least one antibiotic are disclosed. The local anesthetic has a peak effect no later than about 10 minutes after administration to a mammal, and the anesthetic and anti-inflammatory have a half-life of no greater than about 36 hours after administration. The pharmaceutical composition, thus, advantageously provides rapid relief of pain with a substantially low residual accumulation of active components so that the pharmaceutical composition can be repeatedly or continuously administered to a wound. Embodiments include preparing a medicinal solution including Lidocaine as the local anesthetic, Hydrocortisone sodium succinate as the anti-inflammatory agent, Chloramphenicol as the antibiotic agent and, optionally, Heparin as an anticoagulant.Type: GrantFiled: November 30, 1999Date of Patent: May 27, 2003Inventor: Douglas William McKay
-
Patent number: 6562855Abstract: A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.Type: GrantFiled: December 11, 2001Date of Patent: May 13, 2003Inventors: Nicholas Peter Franks, Mervyn Maze
-
Patent number: 6552064Abstract: Melatonin (N-acetyl-5-methoxytryptamine), or its biologically active analogues, are used to induce anesthesia.Type: GrantFiled: August 10, 2001Date of Patent: April 22, 2003Assignee: University of Iowa Research FoundationInventor: Mohamed Naguib Attala
-
Patent number: 6521259Abstract: A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when inplanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.Type: GrantFiled: March 10, 2000Date of Patent: February 18, 2003Assignee: Euro-Celtique S.A.Inventors: Mark Chasin, Richard Sackler, Ronald M. Burch, Paul Goldenheim, Joseph Tigner
-
Patent number: 6509028Abstract: Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the nasal cavity and buccal cavity. To relieve pain, the compositions or the invention are topically applied directly to the affected area.Type: GrantFiled: June 17, 2002Date of Patent: January 21, 2003Assignee: EpiCept CorporationInventors: Robert O. Williams, Feng Zhang, John J. Koleng, Gavril W. Pasternak, Yuri A. Kolesnikov
-
Patent number: 6468982Abstract: Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule that comprises a nucleotide sequence that encodes a protein which comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen, a hyperproliferative cell associated protein or a protein associated with autoimmune disease respectively. In each case, nucleotide sequence is operably linked to regulatory sequences to enable expression in the cells. The nucleic acid molecule is free of viral particles and capable of being, expressed in said cells. The cells may be contacted cells with a cell stimulating agent. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed.Type: GrantFiled: June 23, 1997Date of Patent: October 22, 2002Assignees: The Trustees of the University of Pennsylvania, The Wistar InstituteInventors: David B. Weiner, William V. Williams, Bin Wang
-
Patent number: 6432401Abstract: Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.Type: GrantFiled: May 11, 2001Date of Patent: August 13, 2002Assignee: Novalar Pharmaceuticals, Inc.Inventors: Eckard Weber, Howard I. Katz
-
Patent number: 6426339Abstract: The use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent, is disclosed.Type: GrantFiled: April 3, 2000Date of Patent: July 30, 2002Assignee: Children's Medical Center CorporationInventors: Charles B. Berde, Robert S. Langer, Joanne Curley, Jenny Castillo
-
Patent number: 6413987Abstract: The present invention relates to new aminoindane piperidine compounds, the method of using aminoindane compounds as local anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.Type: GrantFiled: June 6, 2000Date of Patent: July 2, 2002Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen
-
Patent number: 6361319Abstract: A method of decreasing the permeabilty of dentin by the application of an effective amount of oxalic acid potassium salt, dihydrate in an aqueous solution at a pH of about 2.0 to 4.0 to the dentin.Type: GrantFiled: December 20, 2000Date of Patent: March 26, 2002Inventor: Charles E. Cox
-
Patent number: 6355705Abstract: A polymethacrylate or other bone cement composition having analgesic properties is described. Bone cements containing up to 5% by weight of a local anaesthetic agent, such as lidocaine, have been demonstrated to elute sufficient lidocaine to provide an analgesic effect in vivo.Type: GrantFiled: April 1, 1997Date of Patent: March 12, 2002Assignee: Queen's University at KingstonInventors: David M. Bond, John F. Rudan
-
Patent number: 6350465Abstract: A method of treating headaches by blocking the sphenopalatine ganglion comprises using a first device to anesthetize a front portion of the nasal cavity. A second device is used to anesthetize a rear portion of the nasal cavity. After these priming anesthetizations, a primary pain medication delivery device is used to discharge an anesthetic to the sphenopalatine ganglion to treat the headache.Type: GrantFiled: January 17, 2001Date of Patent: February 26, 2002Inventors: Murali M. R. Jonnalagadda, Venkata Thirumala Devi-Jonnalagadda
-
Patent number: 6309625Abstract: Composition and methods that include potassium nitrate for whitening and/or reducing tooth sensitivity. The dental compositions may optionally include a dental bleaching agent, such as hydrogen peroxide or carbamide peroxide. The dental compositions may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray and placed over the person's teeth. In that case, the dental compositions will include a tackifying agent, such as carboxypolymethylene, dispersed within a solvent, which assists the composition in retaining the dental tray over the person's teeth as a result of the adhesive properties of the dental composition rather than due to mechanical interlocking of the tray over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.Type: GrantFiled: November 12, 1998Date of Patent: October 30, 2001Assignee: Ultradent Products, Inc.Inventors: Steven D. Jensen, Dan E. Fischer
-
Patent number: 6306370Abstract: Composition and methods that include potassium nitrate for whitening and/or reducing tooth sensitivity. The dental compositions may optionally include a dental bleaching agent, such as hydrogen peroxide or carbamide peroxide. The dental compositions may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray and placed over the person's teeth. In that case, the dental compositions will include a tackifying agent, such as carboxypolymethylene, which assists the composition in retaining the dental tray over the person's teeth as a result of the adhesive properties of the dental composition rather than due to mechanical interlocking of the tray over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.Type: GrantFiled: November 12, 1998Date of Patent: October 23, 2001Assignee: Ultradent Products, Inc.Inventors: Steven D. Jensen, Dan E. Fischer
-
Patent number: 6297290Abstract: The present invention relates to a novel aqueous composition based on a compound modulating the reactivity of nerve fibers. It relates more particularly to a pharmaceutical composition for topical use on a human or animal body and intended to anesthetize the skin or the mucous membranes or to treat pruritus.Type: GrantFiled: September 4, 1998Date of Patent: October 2, 2001Assignee: Centre International de Recherches Dermatoloques Galderma (C.I.R.D. Galderma)Inventors: Anne-Emmanuelle Guise, Josiane Allec, Karen Ctorza
-
Patent number: 6284805Abstract: A plastics container containing a sterile aqueous solution of an acid addition salt of a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecaboxamide, wherein the solution is buffered.Type: GrantFiled: November 3, 1999Date of Patent: September 4, 2001Assignee: Darwin Discovery, Ltd.Inventor: Stephen Brown
-
Patent number: 6251371Abstract: The present invention relates to use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and the preparation for this purpose. It is known to use dichlorobenzyl alcohol (2,4-DCBA) as an agent against bacteria and fungi, i.e. as a disinfectant. By the present invention it has, however, surprisingly turned out that dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, is also useful for treatment of inflammation. The invention also relates to a preparation containing dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, for topical treatment of inflammation, which can be applied onto skin or mucosa in the form of an ointment, a cream, a gel or a solution. Thus, the preparation has turned out to be effective against a variety of inflammatory conditions including skin diseases, such as pruritus and psoriasis, insect bites and stings.Type: GrantFiled: August 30, 1999Date of Patent: June 26, 2001Assignee: Bifodan A/SInventors: Hans Holmen, Arne Martinus Pedersen
-
Patent number: 6214387Abstract: Biodegradable controlled release microspheres for the prolonged administration of a local anesthetic agent, and a method for the manufacture thereof are disclosed. The microspheres are formed of a biodegradable polymer degrading significantly within a month, with at least 50% of the polymer degrading into non-toxic residues which are removed by the body within a two week period. Useful polymers include polyanhydrides, polylactic acid-glycolic acid copolymers and polyorthoesters containing a catalyst; polylactic acid-glycolic acid copolymers are preferred. Local anesthetics are incorporated into the polymer using a method that yields a uniform dispersion, preferably solvent casting. Prolonged release is obtained by incorporation of a glucocorticoid into the polymeric matrix or by co-administration of the glucocorticoid with the microspheres. The type of anesthetic and the quantity are selected based on the known pharmaceutical properties of these compounds.Type: GrantFiled: September 17, 1997Date of Patent: April 10, 2001Assignee: Children's Medical Center CorporationInventors: Charles B. Berde, Robert S. Langer
-
Patent number: 6143736Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.Type: GrantFiled: July 8, 1999Date of Patent: November 7, 2000Assignee: CoCensys, Inc.Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp